Login
Companies $NEO
$15.41 +$0.00 (0.0%) After hours
NEOGENOMICS INC logo

NEOGENOMICS INC

neogenomics.com

What Do They Do?

Provides cancer testing and expert interpretation for medical practices, hospitals and laboratories, and pharmaceutical companies.

How Do They Make Money?

Clinical tests are billed to clients and health insurers after results reach the ordering physician; pharmaceutical and biotech clients and other research groups are billed for completed service units, with some contracts including upfront fees as work proceeds. Data is licensed as retrospective records upon delivery or as prospective feeds over time.

revenue
SegmentShareRevenue
Client direct billing
Sold outright

71%
FY2022: 73%
Commercial insurance
Sold outright

16%
FY2022: 14%
Medicare and other government
Sold outright

12%
FY2022: 13%
Self-pay
Sold outright
<0.1%
FY2022: <0.1%

Who Are Their Customers?

Community pathology and oncology practices, hospitals and academic centers use cancer testing and interpretation services; pharmaceutical firms buy research testing and data services. The company’s sales and business-development teams work directly with clinical clients and sponsors.

Do Revenues Turn Into Profits?

No. It lost $108M in FY2025.

Operating income, FY2025
−16% of revenue
▼ −26% (Loss) vs FY2024 (−$92.1M, −14%)
Net income, FY2025
−15% of revenue
▼ −37% (Loss) vs FY2024 (−$78.7M, −12%)
Free cash flow, FY2025
−3% of revenue
▲ +36% (Loss) vs FY2024 (−$34M, −5%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +11%
vs $187.8M in Q3 FY2025
Net income
▲ +72% (Loss)
vs −$27.1M in Q3 FY2025
Client direct billing share of revenue vs 70.4% in Q3 FY2025
  • Jul 28, 2026 Raised full-year revenue and adjusted EBITDA guidance Raised 2026 revenue guidance to $802–$806 million and adjusted EBITDA guidance to $56–$58 million.

Growing. Revenue grew 50% in 4 years, from $484.3M in FY2021 to $727.3M in FY2025, about 11% a year.

Oncology data licensing The older report described expanding informatics and data tools to help stakeholders identify trial patients and support decisions; the latest report describes licensed de-identified records and prospective data feeds as oncology data solutions.

Revenue over time
Client direct billing Commercial insurance Medicare and other government Self-pay
$1B$500M$0

Who Do They Compete With?

Competes with Quest Diagnostics, Laboratory Corporation of America, ARUP, Guardant Health, Natera, Exact Sciences, Caris Life Science, Tempus AI, and Myriad Genetics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support